CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Safety and Effectiveness of Intravenous Artesunate for Treatment of Severe Malaria in the United States—April 2019 Through December 2020
-
12 06 2021
-
-
Source: Clin Infect Dis. 73(11):1965-1972
[PDF-458.83 KB]
Details:
-
Alternative Title:Clin Infect Dis
-
Personal Author:
-
Description:Background.
Severe malaria can be deadly and requires treatment with intravenous artesunate (IVAS). The Centers for Disease Control and Prevention provided IVAS starting 1 April 2019 for all patients with severe malaria in the United States. This study describes the safety and effectiveness of IVAS in these patients.
Methods.
Patients meeting criteria for severe malaria April 2019–December 2020 who received IVAS were included. Demographic, clinical, laboratory, adverse event, and outcome information were collected. Clinical presentation, time to reach 1% and 0% parasitemia, adverse events, and death were described using proportions, medians, interquartile range (IQR), and tests of significance for differences in proportions.
Results.
Of 280 patients included, the majority were male (61.4%), Black (75.0%), with a median age of 35 years (IQR: 15.8–53.9). Most had Plasmodium falciparum (83.6%) with median parasitemia of 8.0% (IQR: 4.6–13.2). Of 170 patients with information, 159 (93.5%) reached ≤1% parasitemia by the third IVAS dose with a median time of 17.6 hours (IQR: 10.8–28.8), and 0% parasitemia in a median of 37.2 hours (IQR 27.2–55.2). Patients with parasite densities >10% and those requiring adjunct therapy had significantly higher parasite clearance times. Adverse events associated with IVAS were reported in 4.8% (n = 13 of 271). Eight patients had post-artesunate delayed hemolysis that resolved. There were 5 (1.8%) deaths, all attributable to severe malaria.
Conclusions.
IVAS is a safe and effective drug for the treatment of severe malaria in the United States; timely administration can be lifesaving.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:34314501
-
Pubmed Central ID:PMC10959111
-
Document Type:
-
Funding:
-
Volume:73
-
Issue:11
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
